Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIX3 antisense RNA 1 (SIX3-AS1) is a long non-coding RNA transcribed from the distal promoter region of the SIX3 gene, which encodes a homeodomain transcription factor critical for eye and neural development. SIX3-AS1 is highly expressed in developing retina and hypothalamus, where it functions as a molecular scaffold to recruit chromatin-modifying enzymes (such as Ezh2 of the PRC2 complex) and transcriptional coregulators (such as Eya proteins), thereby modulating the activity of SIX3 and its target genes without altering SIX3 mRNA or protein expression levels. Experimental evidence in mouse models demonstrates its essential role in retinal cell specification and neural development, with epistatic interactions between SIX3 and SIX3-AS1. Although considered a potential therapeutic target due to its regulatory functions, there are currently no approved drugs known to interact specifically with SIX3-AS1[1][3][4].
Scaffold for chromatin-modifying enzymes (such as Ezh2, PRC2 members) Modulates activity of transcriptional regulators (interacts with Eya family proteins)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SIX3 antisense RNA 1 (SIX3-AS1).